Home Featured Page 266

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Small Pharma Provides Update to Patent Portfolio Including Receipt of an...

Psilocybin and the Will to Live

Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

Field Trip Health Ltd. Announces DTC Eligibility

Nova Mentis Launches Autism Clinical Study

Can Psychedelics Provide Relief for Autistic Individuals?

Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading...

Entheon Biomedical Lists on OTCQB Venture Market

Red Light Holland Receives Patent Pending Status For ‘Find Your Dose’...

Mydecine Announces Partnership with LeadGen Labs

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.